Creating a database to understand sleep issues in Smith-Magenis Syndrome
Development of Clinical Database of Individuals With Smith-Magenis Syndrome
This study is collecting information about sleep problems in people with Smith-Magenis Syndrome to help understand and manage these issues better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 3 Years to 65 Years |
| Sex | All |
| Sponsor | Vanda Pharmaceuticals Industry-sponsored |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Trial ID | NCT03154697 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a clinical database focused on the sleep disturbances experienced by individuals with Smith-Magenis Syndrome (SMS). The data collected will contribute to a larger patient registry that seeks to raise awareness about SMS and its associated sleep problems. By gathering detailed information from parents or legal guardians of affected individuals, the study will help identify patterns and potential interventions for managing sleep disturbances in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are parents or legal guardians of individuals diagnosed with Smith-Magenis Syndrome.
Not a fit: Patients who do not have a legal guardian or are not diagnosed with Smith-Magenis Syndrome will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of sleep disturbances in patients with Smith-Magenis Syndrome.
How similar studies have performed: While this approach is focused on a specific syndrome, similar observational studies have successfully contributed to understanding sleep disturbances in other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Parent or legal guardian of individual with Smith-Magenis Syndrome Exclusion Criteria: * Not legal guardian of individual with SMS
Where this trial is running
Washington D.C., District of Columbia
- Vanda Pharmaceuticals — Washington D.C., District of Columbia, United States (Recruiting)
Study contacts
- Study coordinator: Vanda Pharmaceuticals
- Email: clinicaltrials@vandapharma.com
- Phone: 202-734-3400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.